The Oncology Companion Diagnostic Market was Valued at USD 4.12 billion in 2023 and is projected to
This report points to the increasing incidence and prevalence of cancer by type and region, fueling the increasing use of companion diagnostics for tailored treatment strategies. The research analyzes healthcare expenditure on oncology diagnostics by different funding streams, such as government, commercial, private, and out-of-pocket spending, with a focus on regional differences in investment. In addition, it examines biomarker-specific test adoption and market trends, gauging how progress in point-of-care and laboratory testing is refining early detection and treatment accuracy.